PMID- 33183433
OWN - NLM
STAT- MEDLINE
DCOM- 20210609
LR  - 20210609
IS  - 1533-4899 (Electronic)
IS  - 1533-4880 (Linking)
VI  - 21
IP  - 2
DP  - 2021 Feb 1
TI  - Preparation of Poly[lactic-co-glycolic] Acid Nanospheres and Its Role in Hepatoma 
      Cells.
PG  - 977-986
LID - 10.1166/jnn.2021.18627 [doi]
AB  - Poly[lactic-co-glycolic] acid (PLGA) targeting nanoparticles AFP/PLGA/Dt(386), 
      loaded with Dt(386) plasmid of diphtheria toxin gene, modified by Alpha 
      fetoprotein (AFP) monoclonal antibody, is prepared. Its physical and chemical 
      properties and its effect on HepG2 cells are studied. Firstly, Dt(386) expression 
      plasmid pET11a/Dt(386) is constructed and PLGA nanoparticles are prepared by 
      emulsion solvent evaporation (ESE). Scanning electron microscope (SEM) is used to 
      observe its morphology. Laser Particle Sizer is used to measure the particle 
      size. In addition, the encapsulation efficiency, drug loading and in vitro 
      release rate of PLGA nanoparticles are measured. Carboxy fluorescein and 
      rhodamine fluorescein are used to double label IgG/PLGA/Dt(386) and 
      AFP/PLGA/Dt(386) nanospheres, respectively, the entry of nanospheres into HepG2 
      cells are observed at 3 h and 12 h. The effect of AFP/PLGA/Dt(386) nanospheres on 
      the migration of HepG2 cells is examined by wounding healing assay. Transwell 
      chamber experiment is used to detect the effect of AFP/PLGA/Dt(386) nanospheres 
      on the invasion of HepG2 cells. MTT method is utilized to determine the 
      inhibitory activity of nanoparticles on HepG2 cell proliferation. After treated 
      with IgG/PLGA/Dt(386) and AFP/PLGA/Dt(386) nanoparticles for 48 hours, flow 
      cytometry is used to detect the apoptosis rate and cell cycle of HepG2 cells in 
      each group. The results show that the prepared nanospheres have regular 
      morphology, flat surface, average particle size of 265.72+/-12.46 nm, zeta 
      potential of -18.15 mV. The average entrapment efficiency and drug loading are 
      78.48+/-1.71% and 3.16+/-0.35%, respectively. The nanoparticles release slowly and 
      stably in vitro. At the 10th day, the release rate reaches 75.13%. PLGA 
      nanospheres can effectively protect DNA from nuclease degradation. The results 
      show that AFP/PLGA/Dt(386) nanospheres have biological targeting effect and can 
      be enriched in cells. AFP/PLGA/Dt(386) nanoparticles can significantly inhibit 
      the migration, invasion and proliferation of HepG2 cells, and promote apoptosis.
FAU - Shi, Zhongxing
AU  - Shi Z
AD  - Department of Interventional Radiology, The Second Affiliated Hospital of Harbin 
      Medical University, Harbin 150086, Heilongjiang Province, China.
FAU - Li, Jinping
AU  - Li J
AD  - Department of Radiology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, Heilongjiang Province, China.
FAU - Liang, Hongwei
AU  - Liang H
AD  - Department of Radiology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, Heilongjiang Province, China.
FAU - Hu, Hongbo
AU  - Hu H
AD  - Department of Radiology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, Heilongjiang Province, China.
FAU - Jiang, Huijie
AU  - Jiang H
AD  - Department of Radiology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin 150086, Heilongjiang Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Nanosci Nanotechnol
JT  - Journal of nanoscience and nanotechnology
JID - 101088195
RN  - 0 (Drug Carriers)
RN  - 0 (Glycols)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
SB  - IM
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Drug Carriers
MH  - Glycols
MH  - Humans
MH  - Lactic Acid
MH  - *Liver Neoplasms/drug therapy
MH  - *Nanoparticles
MH  - *Nanospheres
MH  - Particle Size
MH  - Polyglycolic Acid
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
EDAT- 2020/11/14 06:00
MHDA- 2021/06/10 06:00
CRDT- 2020/11/13 05:34
PHST- 2020/11/13 05:34 [entrez]
PHST- 2020/11/14 06:00 [pubmed]
PHST- 2021/06/10 06:00 [medline]
AID - 10.1166/jnn.2021.18627 [doi]
PST - ppublish
SO  - J Nanosci Nanotechnol. 2021 Feb 1;21(2):977-986. doi: 10.1166/jnn.2021.18627.